Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh

In low-resource settings, IGlar can be a cost-effective alternative to NPH, largely due to reduced nocturnal hypoglycemia, but the delivery device for the insulin has a major impact on the costs and cost-effectiveness comparisons.